GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...

The review by the EMA follows the U.S. Food and Drug Administration's (FDA) acceptance on January 8, 2025, of the same prefilled syringe for consideration. The vaccine, which has been available in ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix for the prevention of shingles.

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

GSK plc announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun reviewing a prefilled syringe form of Shingrix, GSK's vaccine for shingles ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

Also in vaccines, GSK’s star Shingles vaccine Shingrix saw sales drop 4% at constant exchange rates to 848 million pound sterling ($1.06 billion) in the last three months of 2024. An overall ...

GSK’s shingles vaccine has been approved in the European Union for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults aged 50 years and older since 2018; and in adults 18 ...